Successful use of rasagiline in combination with two antidepressants: A case report

Innovations in Clinical Neuroscience

Volumn 9, Issue 11-12, 2012, Pages 39-41

  Kaur, Narpinder ^a   Madan, Rohit ^a   Sharma, Ashish ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bupropion; Depression; Parkinson's disease; Rasagiline; Venlafaxine

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; RASAGILINE; THYROXINE; TOLTERODINE; VENLAFAXINE;

ADULT; ANHEDONIA; ARTICLE; BRADYKINESIA; BRAIN DEPTH STIMULATION; CASE REPORT; CLINICAL FEATURE; CONCENTRATION LOSS; CRYING; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; DYSARTHRIA; EYELID REFLEX; FACIAL EXPRESSION; FATIGUE; FEMALE; GAIT DISORDER; HOPELESSNESS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INSOMNIA; MAJOR DEPRESSION; MASKING; MEDICAL HISTORY; MOOD DISORDER; MORBID OBESITY; PARKINSON DISEASE; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 84874312040     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. TEMPO trial Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol. 2002; 59:1937-1943.
2. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa inpatients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double blind, parallel-group trial. Lancet. 2005;365:947-954.
3. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol. 2005; 62:241-248.
4. Dowding CH, Shenton CL, Salek, SS. A review of the health-related quality of life and economic impact of Parkinson's disease. Drugs Aging. 2006; 23(9): 693-721.
5. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2007; 23(2):183-189.
6. Goren T, Adar L, Sasson N, Weiss YM. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol. 2010;50(12):1420-1428.
7. Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem. 2007; 103:500-508.
8. Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008; 23:2194-2201.
9. Olanow CW, Rascol O, Hauser R. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009; 361:1268-1278.
10. Parkinson Study Group. A controlled randomized delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004; 61:561-566.
11. Sterling J, Veinberg A, Lerner D, et al. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm 1998;52(Suppl):301-305.
12. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R (+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500-506.
13. Azilect (rasagiline tablets) Prescribing Information, Teva Neuroscience, Kansas City, MO. Dec 2009.
14. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997; 48:1070-1077.